I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Pharmaceutical Contract Manufacturing - A Prelude
COVID-19 Breaks All Things Normal, Pushes Pharmaceutical
Industry Into an Era of Change
COVID-19 Exposes US Pharmaceutical Makers to Risk of Supply
Shortages
US Federal Government & FDA Take Unprecedented, Bold Steps to
Deal with Shortage of Pharmaceuticals
What Does this Spell for Pharmaceutical Outsourcing & Contract
Manufacturing?
Market Outlook
The US and Europe Constitute the Largest Markets for PCM
Asia-Pacific to Drive the PCM Market Growth
Competition
M&A Activity High in the Contract Manufacturing Space
Pharmaceutical Contract Manufacturing - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS
Recent Market Activity

3. MARKET TRENDS & DRIVERS
Strong Rise in Pharmaceutical Sales to Drive Demand for
Pharmaceutical Contract Manufacturing
Global Prescription Drug Sales (In US$ Billion) for the Years
2017, 2019, 2021, 2023 & 2025
Emergence of Outsourcing Trend Bodes Well for CDMOs
Pharmaceutical Contract Manufacturers Adopt Advanced
Manufacturing Technologies
Embracing Emerging Technologies
Exploring & Exploiting New Technologies for Rich Dividends
Rapid Growth of Generic Drugs Drives Demand for Pharma Contract
Manufacturing
Leading Drugs Facing Patent Expiry in the US in 2020
Global Generic Drugs Market Size (in $ Billion) for the Years
2016, 2019, 2020 & 2025
Increasing Significance of Biologic Drugs Fuels Innovations
Supports Demand for Pharmaceutical Contract Manufacturing
Market
Global Biologic Drugs Market Size (in US$ Billion) for the
Years 2019, 2022 & 2025
Aging Population & Increasing Burden of Chronic Diseases Spurs
Pharma Product Sales, Driving Market Growth
Global Aging Population Statistics for the 65+ Age Group in
Million by Geographic Region for the Years 2019, 2025, 2035
and 2050
Global Cancer Incidence: Number of New Cancer Cases in Million
for the Years 2018, 2020, 2025, 2030, 2035 and 2040
World Diabetes and Population Statistics (2019, 2030 & 2045)
Persistent Increase in Pharmaceutical R&D Bodes Well for PCM
Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
Increasing Sales of OTC Drugs Presents an Opportunity for
Pharma Contract Manufacturing Market
Global OTC Drugs Market Breakdown by Product (in %): 2020E
Increasing Outsourcing of Clinical Trials to Emerging Markets
New Technology Promises to Improve Sterile Manufacturing Process
Serialization Drives New Design Developments in Pharma Sector

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Pharmaceutical Contract
Manufacturing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 3: World 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
API/Bulk Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for API/Bulk Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for API/Bulk Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Advanced Drug Delivery Formulations by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Advanced Drug Delivery
Formulations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 9: World 15-Year Perspective for Advanced Drug Delivery
Formulations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Packaging by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 11: World Historic Review for Packaging by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Packaging by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Finished Dose Formulations by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Finished Dose Formulations
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Finished Dose
Formulations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Other Product Types by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Pharmaceutical by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Pharmaceutical by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Pharmaceutical by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Biopharmaceutical by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Biopharmaceutical by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Biopharmaceutical by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Sterile by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 26: World Historic Review for Sterile by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Sterile by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for
Non-Sterile by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 29: World Historic Review for Non-Sterile by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Non-Sterile by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Pharmaceutical Contract Manufacturing Market Presence - Strong
/Active/Niche/Trivial - Key Competitors in the United States
for 2022 (E)
Table 31: USA Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Product Type -
API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging,
Finished Dose Formulations and Other Product Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 33: USA 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Type - Percentage Breakdown of Value
Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations,
Packaging, Finished Dose Formulations and Other Product Types
for the Years 2012, 2021 & 2027

Table 34: USA Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Application -
Pharmaceutical and Biopharmaceutical - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 35: USA Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Pharmaceutical and Biopharmaceutical for the Years
2012, 2021 & 2027

Table 37: USA Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by End-Use - Sterile and
Non-Sterile - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Pharmaceutical Contract
Manufacturing by End-Use - Percentage Breakdown of Value Sales
for Sterile and Non-Sterile for the Years 2012, 2021 & 2027

CANADA
Table 40: Canada Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Product Type -
API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging,
Finished Dose Formulations and Other Product Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 42: Canada 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Type - Percentage Breakdown
of Value Sales for API/Bulk Drugs, Advanced Drug Delivery
Formulations, Packaging, Finished Dose Formulations and Other
Product Types for the Years 2012, 2021 & 2027

Table 43: Canada Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Application -
Pharmaceutical and Biopharmaceutical - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 44: Canada Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Pharmaceutical and Biopharmaceutical for the
Years 2012, 2021 & 2027

Table 46: Canada Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by End-Use - Sterile and
Non-Sterile - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Pharmaceutical
Contract Manufacturing by End-Use - Percentage Breakdown of
Value Sales for Sterile and Non-Sterile for the Years 2012,
2021 & 2027

JAPAN
Pharmaceutical Contract Manufacturing Market Presence - Strong
/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Table 49: Japan Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Product Type -
API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging,
Finished Dose Formulations and Other Product Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 51: Japan 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Type - Percentage Breakdown of Value
Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations,
Packaging, Finished Dose Formulations and Other Product Types
for the Years 2012, 2021 & 2027

Table 52: Japan Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Application -
Pharmaceutical and Biopharmaceutical - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 53: Japan Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Pharmaceutical and Biopharmaceutical for the Years
2012, 2021 & 2027

Table 55: Japan Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by End-Use - Sterile and
Non-Sterile - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Pharmaceutical Contract
Manufacturing by End-Use - Percentage Breakdown of Value Sales
for Sterile and Non-Sterile for the Years 2012, 2021 & 2027

CHINA
Pharmaceutical Contract Manufacturing Market Presence - Strong
/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
Table 58: China Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Product Type -
API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging,
Finished Dose Formulations and Other Product Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 60: China 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Type - Percentage Breakdown of Value
Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations,
Packaging, Finished Dose Formulations and Other Product Types
for the Years 2012, 2021 & 2027

Table 61: China Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Application -
Pharmaceutical and Biopharmaceutical - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 62: China Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Pharmaceutical and Biopharmaceutical for the Years
2012, 2021 & 2027

Table 64: China Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by End-Use - Sterile and
Non-Sterile - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Pharmaceutical Contract
Manufacturing by End-Use - Percentage Breakdown of Value Sales
for Sterile and Non-Sterile for the Years 2012, 2021 & 2027

EUROPE
Pharmaceutical Contract Manufacturing Market Presence - Strong
/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Table 67: Europe Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Pharmaceutical Contract
Manufacturing by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK and
Rest of Europe Markets for Years 2012, 2021 & 2027

Table 70: Europe Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Product Type -
API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging,
Finished Dose Formulations and Other Product Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 72: Europe 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Type - Percentage Breakdown
of Value Sales for API/Bulk Drugs, Advanced Drug Delivery
Formulations, Packaging, Finished Dose Formulations and Other
Product Types for the Years 2012, 2021 & 2027

Table 73: Europe Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Application -
Pharmaceutical and Biopharmaceutical - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 74: Europe Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Pharmaceutical and Biopharmaceutical for the
Years 2012, 2021 & 2027

Table 76: Europe Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by End-Use - Sterile and
Non-Sterile - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Pharmaceutical
Contract Manufacturing by End-Use - Percentage Breakdown of
Value Sales for Sterile and Non-Sterile for the Years 2012,
2021 & 2027

FRANCE
Pharmaceutical Contract Manufacturing Market Presence - Strong
/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
Table 79: France Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Product Type -
API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging,
Finished Dose Formulations and Other Product Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 81: France 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Type - Percentage Breakdown
of Value Sales for API/Bulk Drugs, Advanced Drug Delivery
Formulations, Packaging, Finished Dose Formulations and Other
Product Types for the Years 2012, 2021 & 2027

Table 82: France Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Application -
Pharmaceutical and Biopharmaceutical - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 83: France Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Pharmaceutical and Biopharmaceutical for the
Years 2012, 2021 & 2027

Table 85: France Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by End-Use - Sterile and
Non-Sterile - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Pharmaceutical
Contract Manufacturing by End-Use - Percentage Breakdown of
Value Sales for Sterile and Non-Sterile for the Years 2012,
2021 & 2027

GERMANY
Pharmaceutical Contract Manufacturing Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2022:
(E)
Table 88: Germany Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Product Type -
API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging,
Finished Dose Formulations and Other Product Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 89: Germany Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 90: Germany 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Product Type - Percentage Breakdown
of Value Sales for API/Bulk Drugs, Advanced Drug Delivery
Formulations, Packaging, Finished Dose Formulations and Other
Product Types for the Years 2012, 2021 & 2027

Table 91: Germany Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Application -
Pharmaceutical and Biopharmaceutical - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 92: Germany Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 93: Germany 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Pharmaceutical and Biopharmaceutical for the
Years 2012, 2021 & 2027

Table 94: Germany Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by End-Use - Sterile and
Non-Sterile - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Pharmaceutical
Contract Manufacturing by End-Use - Percentage Breakdown of
Value Sales for Sterile and Non-Sterile for the Years 2012,
2021 & 2027

ITALY
Table 97: Italy Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Product Type -
API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging,
Finished Dose Formulations and Other Product Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Italy Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 99: Italy 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Type - Percentage Breakdown of Value
Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations,
Packaging, Finished Dose Formulations and Other Product Types
for the Years 2012, 2021 & 2027

Table 100: Italy Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Application -
Pharmaceutical and Biopharmaceutical - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 101: Italy Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 102: Italy 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Application - Percentage Breakdown of
Value Sales for Pharmaceutical and Biopharmaceutical for the
Years 2012, 2021 & 2027

Table 103: Italy Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by End-Use - Sterile and
Non-Sterile - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 104: Italy Historic Review for Pharmaceutical Contract
Manufacturing by End-Use - Sterile and Non-Sterile Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 105: Italy 15-Year Perspective for Pharmaceutical
Contract Manufacturing by End-Use - Percentage Breakdown of
Value Sales for Sterile and Non-Sterile for the Years 2012,
2021 & 2027

UNITED KINGDOM
Pharmaceutical Contract Manufacturing Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2022 (E)
Table 106: UK Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Product Type -
API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging,
Finished Dose Formulations and Other Product Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: UK Historic Review for Pharmaceutical Contract
Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug
Delivery Formulations, Packaging, Finished Dose Formulations
and Other Product Types Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 108: UK 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Product Type - Percentage Breakdown of Value
Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations,
Packaging, Finished Dose Formulations and Other Product Types
for the Years 2012, 2021 & 2027

Table 109: UK Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by Application -
Pharmaceutical and Biopharmaceutical - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 110: UK Historic Review for Pharmaceutical Contract
Manufacturing by Application - Pharmaceutical and
Biopharmaceutical Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 111: UK 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Application - Percentage Breakdown of Value
Sales for Pharmaceutical and Biopharmaceutical for the Years
2012, 2021 & 2027

Table 112: UK Recent Past, Current & Future Analysis for
Pharmaceutical Contract Manufacturing by End-Use - Sterile and
Non-Sterile - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Please contact our Customer Support Center to get the complete Table of Contents